EXELExelixis, Inc.

$59.86+49% 1Y
Latest close: a new 52-week highOct 9, 2026what changed →

Is the business good?

Good

A genuinely good business: earnings fully cash-backed (1.5×), margins widening, and elite returns on assets.

3 good, 1 neutral
Fundamental health (F-score)6 / 9SEC EDGAR · Jan 2, 2026

Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.47×derived · Jul 3, 2026

Operating profit is fully backed by cash.

Margin direction, 3 years+31.8 pts

Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.

Where ROE comes from30% ROA

High-quality, exceptional returns on the assets themselves, not leverage. ROE 39% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionbetter than 68% of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is EXEL?

Exelixis, Inc. earns 76% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.

76%

Return on invested capital · cost of capital 9.0% · 67 points above what the capital costs: growth creates value

Operating margin
40%

Operating margin · Biotechnology median −77% · 12 months to Q2 2026

Cash conversion
1.47×

Cash conversion · 1.42× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
−8.7%

Share count, year on year · bought back, each share owns more of the company

Operating margin by fiscal year
YearOperating margin
FY202011%
FY202120%
FY202213%
FY20239.3%
FY202428%
FY202538%
Details›
Gross margin12 months to Q2 2026
96%
Operating margin12 months to Q2 2026
40%
Net margin12 months to Q2 2026
35%
Free cash flow margin
48%
R&D as % of revenue
34%
Revenue, trailing twelve months
$2.44B
Free cash flow, trailing twelve months
$1.17B
Net income, trailing twelve months
$861M
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
76%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.